Sentiment-Signal
21,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
13.6
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | CYTOKINETICS INC |
|---|---|
| Ticker | CYTK |
| CIK | 0001061983 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 23282Q605 |
|---|---|
| ISIN | US23282Q6055 |
| Typ | Common Stock |
| Marktkapitalisierung | 7,31 Mrd. USD |
| Beta | 0,48 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 88,039,000 | -784,955,000 | -6.54 | 1,424,537,000 | -659,625,000 |
| 2025-09-30 | 10-Q | 1,936,000 | -306,178,000 | -2.55 | 1,436,557,000 | -521,123,000 |
| 2025-06-30 | 10-Q | 66,769,000 | -134,370,000 | -1.12 | 1,225,635,000 | -368,720,000 |
| 2025-03-31 | 10-Q | 1,579,000 | -161,376,000 | -1.36 | 1,264,051,000 | -266,413,000 |
| 2024-12-31 | 10-K | 18,474,000 | -589,526,000 | -5.26 | 1,401,673,000 | -135,372,000 |
| 2024-09-30 | 10-Q | 463,000 | -160,545,000 | -1.36 | 1,436,060,000 | -13,911,000 |
| 2024-06-30 | 10-Q | 249,000 | -143,318,000 | -1.31 | 1,523,788,000 | 108,550,000 |
| 2024-03-31 | 10-Q | 835,000 | -135,643,000 | -1.33 | 808,082,000 | -396,160,000 |
| 2023-12-31 | 10-K | 7,530,000 | -526,244,000 | -5.45 | 824,316,000 | -386,323,000 |
| 2023-09-30 | 10-Q | 378,000 | -129,422,000 | -1.35 | 740,614,000 | -438,801,000 |
| 2023-06-30 | 10-Q | 867,000 | -128,637,000 | -1.34 | 779,899,000 | -333,115,000 |
| 2023-03-31 | 10-Q | 4,613,000 | -131,289,000 | -1.38 | 889,815,000 | -229,020,000 |
| 2022-12-31 | 10-K | 94,588,000 | -388,955,000 | -4.33 | 1,014,775,000 | -107,900,000 |
| 2022-09-30 | 10-Q | 2,515,000 | -142,310,000 | -1.52 | 1,075,961,000 | -15,977,000 |
| 2022-06-30 | 10-Q | 88,968,000 | -19,820,000 | -0.23 | 771,717,000 | 111,414,000 |
| 2022-03-31 | 10-Q | 1,148,000 | -89,445,000 | -1.05 | 856,253,000 | 116,261,000 |
| 2021-12-31 | 10-K | 70,428,000 | -215,314,000 | -2.80 | 841,319,000 | 243,863,000 |
| 2021-09-30 | 10-Q | 5,437,000 | -76,086,000 | -0.95 | 827,539,000 | 249,020,000 |
| 2021-06-30 | 10-Q | 2,843,000 | -61,554,000 | -0.86 | 564,302,000 | 16,489,000 |
| 2021-03-31 | 10-Q | 6,548,000 | -47,104,000 | 577,062,000 | 67,846,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 16,395,123 | 0 | 16,395,123 | 1,041,746,107 | Neu | +100,0% | |
| FMR LLC | 36,692,752 | 0 | 36,692,752 | 847,780,995 | Neu | +100,0% | |
| VANGUARD GROUP INC | 12,048,131 | 0 | 12,048,131 | 765,538,243 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 13,027,063 | 0 | 13,027,063 | 511,603,369 | Neu | +100,0% | |
| STATE STREET CORP | 5,825,295 | 0 | 5,825,295 | 370,139,244 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 22,380,152 | 0 | 22,380,152 | 214,532,776 | Neu | +100,0% | |
| Deep Track Capital, LP | 3,336,998 | 0 | 3,336,998 | 212,032,853 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3,056,017 | 0 | 3,056,017 | 194,213,741 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,882,317 | 0 | 2,882,317 | 183,142,422 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 2,721,158 | 0 | 2,721,158 | 172,902,379 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 6,503,079 | 0 | 6,503,079 | 170,326,215 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1,573,637 | 0 | 1,573,637 | 99,988,895 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 2,651,697 | 0 | 2,651,697 | 91,774,036 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 1,392,053 | 0 | 1,392,053 | 88,451,048 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,383,437 | 0 | 1,383,437 | 87,903,587 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1,380,787 | 0 | 1,380,787 | 87,735,208 | Neu | +100,0% | |
| MORGAN STANLEY | 5,220,301 | 0 | 5,220,301 | 86,023,306 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 1,603,125 | 0 | 1,603,125 | 75,462,518 | Neu | +100,0% | |
| LMR Partners LLP | 12,500,000 | 0 | 12,500,000 | 75,414,000 | Neu | +100,0% | |
| Capital International Investors | 1,178,780 | 0 | 1,178,780 | 74,899,681 | Neu | +100,0% | |
| UBS Group AG | 1,131,456 | 0 | 1,131,456 | 71,892,714 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 976,892 | 0 | 976,892 | 62,071,717 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 934,642 | 0 | 934,642 | 59,387,153 | Neu | +100,0% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 13,631,000 | 0 | 13,631,000 | 59,098,203 | Neu | +100,0% | |
| Fisher Asset Management, LLC | 822,885 | 0 | 822,885 | 52,286,113 | Neu | +100,0% | |
| NORGES BANK | 807,070 | 0 | 807,070 | 51,281,228 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 757,563 | 0 | 757,563 | 48,023,193 | Neu | +100,0% | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 747,983 | 0 | 747,983 | 47,526,840 | Neu | +100,0% | |
| BROWN ADVISORY INC | 731,154 | 0 | 731,154 | 46,457,519 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 579,862 | 0 | 579,862 | 36,844,431 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 545,805 | 0 | 545,805 | 34,680,450 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 540,166 | 0 | 540,166 | 34,322,148 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 537,277 | 0 | 537,277 | 34,138,581 | Neu | +100,0% | |
| Caption Management, LLC | 523,099 | 0 | 523,099 | 33,237,710 | Neu | +100,0% | |
| BARCLAYS PLC | 604,658 | 0 | 604,658 | 32,580,950 | Neu | +100,0% | |
| Aberdeen Group plc | 483,061 | 0 | 483,061 | 30,693,696 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 8,774,017 | 0 | 8,774,017 | 29,502,290 | Neu | +100,0% | |
| Foresite Capital Management IV, LLC | 458,295 | 0 | 458,295 | 29,120,064 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 443,910 | 0 | 443,910 | 28,206,179 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 412,966 | 0 | 412,966 | 26,239,860 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 409,990 | 0 | 409,990 | 26,050,764 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 385,820 | 0 | 385,820 | 24,514,971 | Neu | +100,0% | |
| DAFNA Capital Management LLC | 370,997 | 0 | 370,997 | 23,573,149 | Neu | +100,0% | |
| RHUMBLINE ADVISERS | 356,995 | 0 | 356,995 | 22,683,428 | Neu | +100,0% | |
| ExodusPoint Capital Management, LP | 343,144 | 0 | 343,144 | 21,803,370 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 337,031 | 0 | 337,031 | 21,414,949 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 327,202 | 0 | 327,202 | 20,790,415 | Neu | +100,0% | |
| First Turn Management, LLC | 325,668 | 0 | 325,668 | 20,692,945 | Neu | +100,0% | |
| CITIGROUP INC | 289,501 | 0 | 289,501 | 18,394,893 | Neu | +100,0% | |
| Susquehanna Portfolio Strategies, LLC | 278,429 | 0 | 278,429 | 17,691,379 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7,500 | 65.38 | -490,350.00 | -138,8% | |
| 2026-04-15 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -7,449 | 66.02 | -491,782.98 | -139,2% | |
| 2026-03-18 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1,930 | 62.07 | -119,795.10 | -33,9% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,916 | 62.15 | -181,229.40 | -51,3% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -7,636 | 62.15 | -474,577.40 | -134,3% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -4,397 | 62.15 | -273,273.55 | -77,4% | |
| 2026-03-17 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -4,935 | 62.15 | -306,710.25 | -86,8% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -5,626 | 62.15 | -349,655.90 | -99,0% | |
| 2026-03-16 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1,709 | 61.03 | -104,300.27 | -29,5% | |
| 2026-03-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,907 | 60.72 | -176,513.04 | -50,0% | |
| 2026-03-09 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2,582 | 60.72 | -156,779.04 | -44,4% | |
| 2026-03-09 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7,931 | 60.72 | -481,570.32 | -136,3% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15,000 | 61.87 | -928,050.00 | -262,7% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -11,000 | 61.88 | -680,680.00 | -192,7% | |
| 2026-03-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 61.62 | -54,595.32 | -15,5% | |
| 2026-03-02 | PARSHALL B LYNNE | Director | Open Market Sale | -5,000 | 61.21 | -306,050.00 | -86,6% | |
| 2026-02-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15,000 | 61.93 | -928,950.00 | -263,0% | |
| 2026-02-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 62.10 | -55,020.60 | -15,6% | |
| 2026-01-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15,000 | 60.28 | -904,200.00 | -256,0% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -885 | 63.16 | -55,896.60 | -15,8% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -913 | 62.09 | -56,688.17 | -16,0% | |
| 2025-12-29 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1,809 | 62.44 | -112,953.96 | -32,0% | |
| 2025-12-22 | WIERENGA WENDELL | Director | Open Market Sale | -20,000 | 66.14 | -1,322,800.00 | -374,5% | |
| 2025-12-16 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,200 | 61.24 | -134,728.00 | -38,1% | |
| 2025-12-08 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1,042 | 65.96 | -68,730.32 | -19,5% | |
| 2025-12-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -52,486 | 65.95 | -3,461,451.70 | -979,8% | |
| 2025-12-02 | HENDERSON JOHN T | Director | Open Market Sale | -8,750 | 63.90 | -559,125.00 | -158,3% | |
| 2025-12-02 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,200 | 63.89 | -140,558.00 | -39,8% | |
| 2025-12-01 | Kaye Edward M. MD | Director | Open Market Sale | -28,064 | 66.72 | -1,872,430.08 | -530,0% | |
| 2025-12-01 | Harrington Robert Arthur | Director | Open Market Sale | -2,150 | 66.80 | -143,620.00 | -40,7% | |
| 2025-11-19 | PARSHALL B LYNNE | Director | Open Market Sale | -5,000 | 64.73 | -323,650.00 | -91,6% | |
| 2025-11-18 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,200 | 66.45 | -146,190.00 | -41,4% | |
| 2025-11-11 | Kaye Edward M. MD | Director | Open Market Sale | -5,175 | 65.08 | -336,789.00 | -95,3% | |
| 2025-11-04 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,295 | 59.55 | -136,667.25 | -38,7% | |
| 2025-10-30 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5,000 | 62.86 | -314,300.00 | -89,0% | |
| 2025-10-27 | WIERENGA WENDELL | Director | Open Market Sale | -4,375 | 58.68 | -256,725.00 | -72,7% | |
| 2025-10-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,105 | 58.22 | -122,553.10 | -34,7% | |
| 2025-10-16 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5,000 | 60.03 | -300,150.00 | -85,0% | |
| 2025-10-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 60.56 | -121,120.00 | -34,3% | |
| 2025-10-06 | Kaye Edward M. MD | Director | Open Market Sale | -6,757 | 60.00 | -405,420.00 | -114,8% | |
| 2025-10-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5,000 | 55.05 | -275,250.00 | -77,9% | |
| 2025-09-30 | Kaye Edward M. MD | Director | Open Market Sale | -6,695 | 55.08 | -368,760.60 | -104,4% | |
| 2025-09-23 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 49.28 | -98,560.00 | -27,9% | |
| 2025-09-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5,000 | 49.77 | -248,850.00 | -70,4% | |
| 2025-09-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 51.29 | -102,580.00 | -29,0% | |
| 2025-09-02 | Harrington Robert Arthur | Director | Open Market Sale | -2,150 | 48.67 | -104,640.50 | -29,6% | |
| 2025-09-02 | Kaye Edward M. MD | Director | Open Market Sale | -6,756 | 50.00 | -337,800.00 | -95,6% | |
| 2025-08-19 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 38.31 | -76,620.00 | -21,7% | |
| 2025-08-05 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 36.34 | -72,680.00 | -20,6% | |
| 2025-07-22 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 37.47 | -74,940.00 | -21,2% | |
| 2025-07-08 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 33.76 | -67,520.00 | -19,1% | |
| 2025-06-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 32.91 | -65,820.00 | -18,6% | |
| 2025-06-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -8,659 | 32.04 | -277,434.36 | -78,5% | |
| 2025-06-05 | Kaye Edward M. MD | Director | Open Market Sale | -3,636 | 32.10 | -116,715.60 | -33,0% | |
| 2025-06-03 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 31.88 | -63,760.00 | -18,0% | |
| 2025-05-20 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 31.98 | -63,960.00 | -18,1% | |
| 2025-05-06 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2,000 | 35.01 | -70,020.00 | -19,8% | |
| 2025-05-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -4,002 | 36.68 | -146,793.36 | -41,6% |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| OPPENHEIMER & CO INC | 3,908 | 257,576 | 100.00 |